{"id":27348,"date":"2022-09-19T14:43:53","date_gmt":"2022-09-19T18:43:53","guid":{"rendered":"https:\/\/avalere.com\/?p=27348"},"modified":"2022-09-19T14:46:31","modified_gmt":"2022-09-19T18:46:31","slug":"eom-participation-likely-influenced-by-prior-ocm-experience","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience","title":{"rendered":"EOM Participation Likely Influenced by Prior OCM Experience"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column][vc_column_text]The Oncology Care Model (OCM) was a voluntary, 6-year, episode-based, oncology-focused payment model from Center for Medicare &amp; Medicaid Innovation (CMMI). The model aimed to improve care coordination and reduce costs for Medicare Fee-for-Service (FFS) beneficiaries, and it evaluated total cost of care for 6-month episodes. The OCM concluded June 30, and its successor, the Enhancing Oncology Model (EOM), will begin July 1, 2023.<\/p>\n<p>The EOM methodology design was informed by learnings from the OCM. The CMMI is making several key changes that will affect the number of included beneficiaries and maximize the opportunity for savings to Medicare. The EOM requires practices to immediately take on downside risk and reduces the monthly enhanced oncology services payment per beneficiary per month from $160 to $70, while requiring participants to implement additional redesign activities. Stakeholders are considering what these changes mean for participation in the EOM.<\/p>\n<p>To better understand and predict EOM participation considering lessons learned from OCM, Avalere analyzed OCM performance within the context of practice type and ability to achieve a performance-based payment (PBP).<\/p>\n<h2>Findings<\/h2>\n<p><strong>The majority of OCM episodes were attributed to community-based practices.<\/strong> About two-thirds of the 126 active OCM participants were community-based and accounted for over 80% of overall OCM episode volume. Based on the classifications above, 35% of community practices were considered \u201chigher performing.\u201d<\/p>\n<p>To examine elements of practice success in OCM, Avalere assessed practice performance among community-based practices for Performance Period (PP) 5 through PP8 (episodes initiated between July 2018 and June 2020 and ended by December 2020). Practices were classified into performance categories based on historic performance.<\/p>\n<ul>\n<li>Higher Performing: Earned 3\u20134 PBPs in PP5\u2013PP8 in alternative two-sided risk<\/li>\n<li>Lower Performing: Earned at least 0\u20131 PBPs in PP5\u2013PP8 in alternative two-sided risk<\/li>\n<li>Other: Earned 2 PBPs in PP5\u2013PP8 in alternative two-sided risk<\/li>\n<\/ul>\n<p><strong>Community-based practice performance improved over time. <\/strong>Model savings are achieved when practice expenditures are below the benchmark amount defined by CMMI. From PP5 through PP8, the share of practices with total expenditures below the benchmark amount increased from 59% to 74% (Figure 1), which suggests that performance improved as participants became more familiar with the model. Given the pattern of improved performance over time, experienced OCM practices with demonstrated patterns of achieving PBPs may be positioned more favorably as they contemplate participation in the EOM. EOM participants who have not participated in an OCM or commercial oncology alternative payment model (APM) may experience a learning curve in the first one to two years of the model.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=&#8221;27344&#8243; img_caption=&#8221;Figure 1. Three-Quarters of Community-Based Practices Achieved Savings by PP8 &#8220;][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<strong>Smaller episode volume has been associated with OCM success. <\/strong>Using average episode volume per practice and PP as a measure of practice size, Avalere found that \u201chigher performing\u201d practices were 26% smaller than \u201clower performing\u201d practices (Table 1). Smaller practices may benefit from smaller, more centralized decision-making and dissemination processes that allow them to implement organizational changes more quickly with greater impact on OCM performance.<\/p>\n<p>Two community oncology practices contribute about 20% of OCM volume. To remove potential bias that these practices have on an assessment of average episode count, Avalere also assessed average episode count without these practices. When excluding the largest community oncology practices, \u201chigher performing\u201d practices were 45% smaller than \u201clower performing\u201d practices.<\/p>\n<table id=\"insight\">\n<caption>Table 1. Average Episode Count by Practice Type<\/caption>\n<thead>\n<tr>\n<td><\/td>\n<th colspan=\"2\">All Community Oncology Practices\u200b<\/th>\n<th colspan=\"2\">Excluding Largest Community\u00a0\u200bOncology Practices\u200b<\/th>\n<\/tr>\n<tr>\n<td><\/td>\n<th>Higher Performing\u200b<\/th>\n<th>Lower Performing\u200b<\/th>\n<th>Higher Performing\u200b<\/th>\n<th>Lower Performing\u200b<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Average Episode Count<br \/>\nCommunity practices (n=80)\u200b\u200b<\/strong><\/td>\n<td>217\u200b<\/td>\n<td>294\u200b<\/td>\n<td>120\u200b<\/td>\n<td>219\u200b<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Among the 80 community oncology practices, Avalere observed similar patterns related to average episode expenditure, tumor mix, and OCM methodological adjustment factors across practices (Figure 2).<\/p>\n<ul style=\"margin-bottom: 30px;\">\n<li>Avalere assessed the cost components that make up community oncology episodes\u2019 total cost of care. On average, most costs in PP5\u2013PP8 were attributed to Part B oncolytics followed by Part D oncolytics (Figure 2).<\/li>\n<li>Practices\u2019 tumor mix was very similar across the 80 community oncology practices. The seven tumor types that will be included in the EOM accounted for nearly half of all OCM episodes in PP5\u2013PP8 (Figure 2). Practices considering participation in EOM Risk Arrangement 2 should estimate whether their EOM episode volume will meet the threshold to achieve Qualified Professional (QP) status or partial QP status under the Medicaid and Children\u2019s Health Insurance Program Reauthorization Act, which exempts them from Merit-based Incentive Payment System reporting and, for QP status, earns higher annual payment updates.<\/li>\n<li>To estimate the benchmark amount, the OCM methodology included three adjustment factors: the trend factor, novel therapy adjustment, and experience adjustor. These adjustments aimed to account for a practice\u2019s historic efficiency and cost patterns. Avalere assessed variation across three adjustment factors by participant success category and found that the distribution of these values was very similar and did not drive the likelihood of success.<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=&#8221;27345&#8243; img_caption=&#8221;Figure 2. Average OCM Community Practice Spending and Tumor Mix, PP5\u2013PP8&#8243;][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]\n<p class=\"figure-note\">Note: all other costs include all other Medicare FFS costs during the OCM episode of care.<\/p>\n<p>As community oncology practices further advance participation in APMs, they face challenges to implementing care redesign and taking on more downside risk in a primarily FFS environment. When deciding whether to participate in the EOM and other commercial models, practices must consider APM design in addition to established practice economics in a post-COVID-19 world. Although smaller practice size was associated with higher performance in the OCM, practices of all sizes may engage in the EOM. Characteristics of practices likely to participate in the EOM may include financially higher performing OCM participants, practices with network-level support navigating the model and implementing care transformation, and practices involved in commercial APMs.<\/p>\n<h2>What&#8217;s Next?<\/h2>\n<p>The time between the EOM request for application announcement on June 27, 2022, and the model commencement on July 1, 2023, offers an opportunity for stakeholders to understand the design, model the impact, and engage with CMMI to continue to shape the model. Avalere can help life sciences companies and other stakeholders assess how the EOM will impact practice performance and model-associated revenue streams.<\/p>\n<p><em>Funding for this research was provided by the Community Oncology Alliance. Avalere maintained full editorial control.<\/em><\/p>\n<h2>Methodology<\/h2>\n<p>Avalere replicated CMMI\u2019s OCM methodology using Medicare FFS Part A and B and Part D prescription drug claims data. Episodes were assigned to practices using a proprietary taxpayer identification number mapping algorithm; 124 of the 126 active OCM practices were identified for analysis. OCM practice type (i.e., community vs. hospital-based) was identified using a two-part approach. First, practices were classified according to the most frequent place of service (i.e., physician office for community and hospital outpatient for hospital-based) observed on the cancer-related evaluation and management visits billed during their attributed episodes. Second, a manual review was conducted to reclassify ten practices that were likely hospital-based but had varying billing patterns indicating a physician office place of service.<\/p>\n<p>At the PP level, Avalere defined OCM success based on comparing practices\u2019 actual spending relative to the benchmark amount (i.e., ability to earn a PBP or risk of owing recoupment). For each PP, practices were classified into one of four performance zones based on their distance to benchmark, defined as the ratio of actual spending to benchmark amount. The figure below shows the mapping between performance zone and the distance to benchmark value.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=&#8221;27346&#8243; img_caption=&#8221;Figure 3. OCM Performance Zones (One-Sided vs. Alternative Two-Sided Risk)&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Since performance can vary for a given practice across the four PPs in the analysis, Avalere assessed the number of PPs from PP5 to PP8 for which a practice was estimated to have earned a PBP under an alternative two-sided risk arrangement (i.e., distance to benchmark was -2.5% and below). Practices estimated to have earned three or four PBPs were considered to be \u201chigher performing\u201d while practices estimated to have earned between zero and one PBPs were considered \u201clower performing.\u201d Practices estimated to have earned two PBPs were categorized as \u201cother.\u201d<\/p>\n<p>To keep up with the latest developments in oncology care models, <a href=\"https:\/\/info.avalere.com\/LP=46\">connect with us<\/a>.[\/vc_column_text][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text]The Oncology Care Model (OCM) was a voluntary, 6-year, episode-based, oncology-focused payment model from Center for Medicare &amp; Medicaid Innovation (CMMI). The model aimed to improve care coordination and reduce costs for Medicare Fee-for-Service (FFS) beneficiaries, and it evaluated total cost of care for 6-month episodes. The OCM concluded June 30, and its successor, the&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"content-categories":[143],"class_list":["post-27348","post","type-post","status-publish","format-standard","hentry","category-insights","content-categories-value-based-care","entry","no-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EOM Participation Likely Influenced by Prior OCM Experience | Avalere Health Advisory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EOM Participation Likely Influenced by Prior OCM Experience | Avalere Health Advisory\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text]The Oncology Care Model (OCM) was a voluntary, 6-year, episode-based, oncology-focused payment model from Center for Medicare &amp; Medicaid Innovation (CMMI). The model aimed to improve care coordination and reduce costs for Medicare Fee-for-Service (FFS) beneficiaries, and it evaluated total cost of care for 6-month episodes. The OCM concluded June 30, and its successor, the&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience\" \/>\n<meta property=\"og:site_name\" content=\"Avalere Health Advisory\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-19T18:43:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-19T18:46:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/19231-1-Madison_Davidson_600x400.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"avalere_wp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:site\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"avalere_wp\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EOM Participation Likely Influenced by Prior OCM Experience | Avalere Health Advisory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience","og_locale":"en_US","og_type":"article","og_title":"EOM Participation Likely Influenced by Prior OCM Experience | Avalere Health Advisory","og_description":"[vc_row][vc_column][vc_column_text]The Oncology Care Model (OCM) was a voluntary, 6-year, episode-based, oncology-focused payment model from Center for Medicare &amp; Medicaid Innovation (CMMI). The model aimed to improve care coordination and reduce costs for Medicare Fee-for-Service (FFS) beneficiaries, and it evaluated total cost of care for 6-month episodes. The OCM concluded June 30, and its successor, the&hellip;","og_url":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience","og_site_name":"Avalere Health Advisory","article_published_time":"2022-09-19T18:43:53+00:00","article_modified_time":"2022-09-19T18:46:31+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/19231-1-Madison_Davidson_600x400.jpg","type":"image\/jpeg"}],"author":"avalere_wp","twitter_card":"summary_large_image","twitter_creator":"@avalerehealth","twitter_site":"@avalerehealth","twitter_misc":{"Written by":"avalere_wp","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience#article","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience"},"author":{"name":"avalere_wp","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/6cea6678c016753ac38b9aad6cff71aa"},"headline":"EOM Participation Likely Influenced by Prior OCM Experience","datePublished":"2022-09-19T18:43:53+00:00","dateModified":"2022-09-19T18:46:31+00:00","mainEntityOfPage":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience"},"wordCount":1390,"commentCount":0,"publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"articleSection":["Insights &amp; Analysis"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience#respond"]}]},{"@type":"WebPage","@id":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience","url":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience","name":"EOM Participation Likely Influenced by Prior OCM Experience | Avalere Health Advisory","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/#website"},"datePublished":"2022-09-19T18:43:53+00:00","dateModified":"2022-09-19T18:46:31+00:00","breadcrumb":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/advisory.avalerehealth.com\/insights\/eom-participation-likely-influenced-by-prior-ocm-experience#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/advisory.avalerehealth.com\/"},{"@type":"ListItem","position":2,"name":"EOM Participation Likely Influenced by Prior OCM Experience"}]},{"@type":"WebSite","@id":"https:\/\/advisory.avalerehealth.com\/#website","url":"https:\/\/advisory.avalerehealth.com\/","name":"Avalere Health Advisory","description":"","publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/advisory.avalerehealth.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/advisory.avalerehealth.com\/#organization","name":"Avalere Health","url":"https:\/\/advisory.avalerehealth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/","url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","contentUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","width":433,"height":47,"caption":"Avalere Health"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/avalerehealth"]},{"@type":"Person","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/6cea6678c016753ac38b9aad6cff71aa","name":"avalere_wp","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b39b7367e9be99e141408d09d07b8853?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b39b7367e9be99e141408d09d07b8853?s=96&d=mm&r=g","caption":"avalere_wp"},"url":"https:\/\/advisory.avalerehealth.com\/author\/avalere_wp"}]}},"_links":{"self":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/27348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/comments?post=27348"}],"version-history":[{"count":7,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/27348\/revisions"}],"predecessor-version":[{"id":27357,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/27348\/revisions\/27357"}],"wp:attachment":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/media?parent=27348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/categories?post=27348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/tags?post=27348"},{"taxonomy":"content-categories","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/content-categories?post=27348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}